Marker Therapeutics Inc (MRKR) Quote

My recollection is they broke even on the sale of the plant to the director. My guess is he did very well for himself. The only hope now is that between TapImmune and AlloVir’s bath water just one of Marker’s products is the baby.

Correction, I just realized, I will be back to even on 7/8ths of my position.
I sold 1/8th of my position at a loss, which lowered my average cost down quite a bit because of the FOMO First In First Out rule.
Posting this just because I don't want to mislead.

Once Again, Thank You. I'm getting too old to remember all of this stuff, heck, I'm watching a TV show, a commercial comes on, and I forget what I was watching.
I'm reading an article on the computer, want to goggle something, minimize the page, go to google, and I forget what I wanted to google, so I have to go back and read the damn article again to remember what I wanted to google.
Yep, this getting old stuff really sucks.
"The future will rest on this next data release over summer so they better make it count." 100% agree.
"It better be close to fully enrolled, anything less than 25 patients, will be unacceptable." 100% agree.
Thanks Again

Marker definitely fumbled the manufacturing plan. I don't believe the facility cost them very much. They rented the space and the modular set up made it fairly economical. If I remember correctly it was set up for roughly $6M - $8M. Not an insane amount in the grand scheme of things. What was going to sink them was the cost to run the facility which was around $11M per year. Again, if I remember correctly. Offloading it was the right move but in hindsight it should have never been built to begin with. Wilson bailed them out by purchasing it regardless of what you think about the price it was sold for.

I have old emails from Peter Hoang regarding the companies decision to build their own facility rather than contract with a CDMO initially and the company's reasoning at the time made sense to me but I do think they failed to factor in the annual cost to run it as well as failed to accurately evaluate the potential time delays they suffered by prioritizing it. All this a long with the fact that they never had a ton of cash to be working with.

In any event, hopefully they are on the right track with finally having an experienced CDMO to handle their manufacturing. The future will rest on this next data release over summer so they better make it count. It better be close to fully enrolled, anything less than 25 patients, and I'm being lenient there, will be unacceptable. There obviously needs to be more CRs and I need to see durability in the initial patients and they better have more data to support their statement that lymphodepletion does improve the results.

If they don't put themselves in a position to start their PII lymphoma trial by mid next year what little faith I have left will quickly vanish.

Thanks

Thank You for the info, you always have the answer. I kind of thought that the MRKR manufacturing plant was somewhat dumb and also shady because IF management is going to build a building, build a plant, spend all that money, then they should KNOW that they will need it and they should KNOW that they have enough money to keep it. You don't make decisions like that thinking 6 months down the road, you do that think 5 and 10 years down the road. If you can't spend all that money and keep it for 10 years, then they could of just did a Cellipont deal back then.
The other thing was, that being at the time of the Wilson sale, it sounded like MRKR was in a bit of a desperate position, that Wilson got a very good deal on it at what would be below it real value, but I don't know, I could be wrong on that one.
Thank You Again. I guess it's now just back to wait and hope.

On track financially? They decimated their shareholders with reverse splits and left them with:

>>Based on the Company’s lack of recurring revenues, anticipated uses of cash and historical recurring cash losses from operating activities, and cash and cash equivalents as of March 31, 2025, the Company anticipates that it will be able to fund its operating expenses and capital expenditure requirements into the first quarter of 2026, assuming no additional grant funds are received. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.

Best thing to happen was removing the contractor from the board. Had to be done. I’ve always liked this T therapy’s chances but they need a more qualified CEO with real wins and experience.

Same crew here as over on NWBO, that’s obvious.🤷🏻‍♂️

The MSA with CellReady was terminated. All future manufacturing will be done through Cellipoint. John Wilson no longer has any part of Marker other than being a shareholder. I don't agree with this but unfortunately it is what it is. I believe Wilson was a major factor in getting the company on track financially and he pumped a lot of his own money into Marker. The company did him dirty.

That being said. The manufacturing agreement with Cellipoint is fine. They should be able to do anything and everything CellReady was doing.

Howdy Phantom, One question I'm a bit confused on. This new Cellipont Bioservices agreement for manufacturing? I thought that was the point of the 2023 agreement with CellReady / John Wilson? I know Marker sold it to get cash and reduce expenses, so what's the deal now. Is somebody doing 401 and another is doing 601? Or is Cellipont doing everything and CellReady doing nothing? Thank You

That depends on what the FDA wants. Marker's pivotal PII AML I believe was planned to have ~160 patients. Kite's Zuma-1 pivotal trial that Yescarta was approved from had about 100 patients so my rough estimate guess would be somewhere around 100 - 150 patients should be sufficient.

Sorry to bother you, how many patients would be sufficient for the phase 2 trial,for that to happen? Once again, thank you.

Thank you

Thanks

No. Their plan is to initiate a pivotal PII. If results are good enough after a pivotal PII then they may be able to forgo the PIII.

I’ve never seen it. Might depend on the disease, of course. A Pll on stellar results with a confirmatory trial was done a number of times.

Question for the smart people, is it possible if they got great results after phase one, that they could go directly to phase 3? Thank you for your opinions

Thanks

👍👍👍

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-and-cellipont-bioservices-announce

Thanks

Thanks

New analyst covering Marker:

https://www.msn.com/en-us/money/top-stocks/brookline-capital-sets-4-target-on-marker-therapeutics-stock/ar-AA1yMlgC

Anyone who bought pre reverse splits is crushed. It's when it becomes a 99. - - -% loss that nearly makes it impossible to ever get back your money. 

I hope to not regret it, but I average down, but it’s still high. I hope everybody who is long gets rewarded.

I would be elated if I was only down 90%. No desire to average down.

I’m going to take a guess and say that they are going to get financing from blue owl capital

Now, if it will only go up another 200% from here to $5.61 ... after 25 years of investing in this ...
... after more than a quarter of a century ... after buying more and more and more ...
after 25 years ... I would get back to even ... Hoorah!

Nice move but still an awful $19M market cap with many shareholders down 90%+.

👍👍👍

My pleasure…

Thank you

https://www.reuters.com/business/healthcare-pharmaceuticals/us-health-secretary-kennedy-looks-fast-tracking-approvals-rare-disease-drugs-2025-06-05/

You’re welcome…

Thanks

8-K out, click link to read complete filing…

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 6, 2025, the Company held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The stockholders considered three proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 24, 2025. Of the 11,314,835 shares outstanding as of the record date, 7,629,048 shares, or 67.43%, were present virtually or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

https://www.sec.gov/Archives/edgar/data/1094038/000110465925057836/tm2517533d1_8k.htm

Thanks looks very promising, the presentation and slides they showed

Agreed! Fresh deck out.

https://ir.markertherapeutics.com/news-events/events-presentations/

Whatever is going on, keep it going

Biotech Management excel at pumping Pl&ll then making Plll’s disappear, these guys are certainly no exception. Shareholders need a real proven leader or sell the company now!

Thank you

Well, they said they enrolled more patients in the first 5 months of 2025 than they did the whole year of 2024. If those first 3 patients were enrolled in 2023 that means they enrolled 6-7 patients in 2024. The study says 9 observable patients at last readout but I feel they had one extra patient enrolled who wasn't observable yet. Too lazy to go back to confirm. If all of this is the case then they enrolled at least 7-8 patients through May. So they're half way to their expected enrollment. If this rate holds they should be fully enrolled by early next year. Still way too long but if results continue as they have it's possible there will be enough meaningful data to move forward without getting to full enrollment.

and we can "hope" that it doesn't take them 5 years to get more than 2 people enrolled in the Phase 2 trial.

The PR clearly states that they are noticing the improvements with lymphodepletion in the APOLLO study. This would imply they are already using it in the study and will not need to do an additional PI. If results hold it will move to a PII and they better make damn sure it will be a pivotal trial.

I'm a little worried, once they've completed there phase one trial in lymphoma rather than go to phase 2 they'll start all over again with a new phase 1. With this new lymphodepletion discovery. Meaning more delays and more dilution for the stock holders.

I have had the white flag out for awhile now, but I ain't ready to wave it just yet, so I will click on the green bull emoji and submit.

Thanks

Thank you

Thank you

It's not surprising that lymphodepletion is helping their therapy. My main issue is they spent the last 6 years hyping up their therapy as "not requiring lymphodepletion" and now they are using lymphodepletion to improve results. I want to know why it took them so damn long to just start doing? I'm all for anything that improves results but I do want to know what caused the company's change of heart.